secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-07-01T12:05:36+00:00
Accession:  0001213900-26-073998
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics granted U.S. patent for stenoparib DRP companion diagnostic through April 2042
--------------------------------------------------------------------------------

- USPTO granted key U.S. patent covering stenoparib-specific Drug Response Predictor (DRP) companion diagnostic.
- Patent term extends into April 2042, providing long-term exclusivity for stenoparib when used with the DRP test.
- Patent covers methods to predict clinical benefit from stenoparib based on tumor gene-expression profiles and patient selection.
- Allarity also has patent protection for stenoparib DRP in Europe and Australia into 2039.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/0001213900-26-073998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026073998/ea0296615-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-073998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer